NPS Pharmaceuticals Rakes in $38.6M to Advance Pipeline

Shaffer, Catherine
September 2010
BioWorld Today;9/17/2010, Vol. 21 Issue 180, p1
The article reports on the public offering launched by NPS Pharmaceuticals Inc., which is expected to generate 38.6 million dollars upon closing on September 21, 2010. The company will use the proceeds to fund its research and development (R&D) efforts in the area of gastrointestinal and endocrine disorders. Francois Nader of NPS talks about the company's Phase III STEPS study of Gattex in short bowel syndrome and Phase III REPLACE study of NPSP558 in hypoparathyroidism.


Related Articles

  • Tissue-Bone Firm BioMimetic Raising $40M in Stock Offering. Hollingsworth, Catherine // BioWorld Today;7/16/2010, Vol. 21 Issue 136, p1 

    The article offers information on the public offering by BioMimetic Therapeutics Inc. The company sold 5 million shares of its common stock at 8.50 U.S. dollars per share and posted net proceeds of approximately 40 million U.S. dollars before overallotments. The proceeds of the offering will be...

  • NPS Pharmaceuticals Prices Upsized Public Offering of Common Stock.  // Biomedical Market Newsletter;5/14/2011, p176 

    The article informs that NPS Pharmaceuticals Inc. (NPS) has announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price of 9.00 dollars per share. NPS has granted the underwriters a 30-day option to purchase up to an aggregate of 1,650,000...

  • Financings Roundup.  // BioWorld Today;9/22/2010, Vol. 21 Issue 183, p3 

    The article reports that NPS Pharmaceuticals Inc. of Bedminster, New Jersey, has closed a public offering of its common stock totaled about 44.4 million dollars.

  • Financings Roundup.  // BioWorld Today;5/30/2013, Vol. 24 Issue 103, p2 

    The article reports that NPS Pharmaceuticals INc. completed its public offering of 6.9 million shares worth 14.53 dollars a share, resulting to net proceeds worth 93.4 million dollars.

  • NPS Takes $145M Advance on Sensipar Royalties from Amgen. Shaffer, Catherine // BioWorld Today;8/17/2011, Vol. 22 Issue 159, p1 

    The article reports on a 145 million U.S. dollars advance on royalties that NPS Pharmaceuticals Inc. will get from the sales of Sensipar/Mimpara drug from Amgen Inc. NPS has also decided to retire its 15.5 percent secured class B notes after redeeming them in September 2011. NPS chief executive...

  • NPS makes progress on drug commercializations. P., Shankar // njbiz;5/11/2009, Vol. 22 Issue 19, p2 

    The article reports on the decision of Bedminster, New Jersey-based NPS Pharmaceuticals to advance two ongoing registration trials for two drugs. The new drug applications are expected by president and chief executive Francois Nader to be filed in late 2010 or early 2011. There was also a...

  • NPS Boosts Treasury with $40M Equity Financing for Pivotal Trials. Harris, Glen // BioWorld Today;8/7/2009, Vol. 20 Issue 151, p1 

    The article reports on the 40 million dollars committed equity deal between NPS Pharmaceuticals Inc. and Azimuth Opportunity Ltd. The deal is expected to help NPS with the Phase III trials for Gattex against short bowel syndrome and NPSP558 for treating hypoparathryrodism. On the other hand,...

  • Financings Roundup.  // BioWorld Today;4/20/2011, Vol. 22 Issue 76, p4 

    The article reports on the completion of a public offering of 12.6 million shares of common stock by Bedminster, New Jersey-based NPS Pharmaceuticals Inc.

  • Financings Roundup.  // BioWorld Today;5/23/2013, Vol. 24 Issue 99, p8 

    The article announces the public offering of NPS Pharmaceuticals Inc. of 6 million shares of stock priced at 14.53 dollars per share.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics